Key result
Tirzepatide significantly reduced systolic blood pressure (median -4.20 mmHg, 95% CI -5.17 to -3.23 for 5 mg) and improved lipid profiles across 5 mg, 10 mg, and 15 mg once-weekly doses.
Why the study?
To quantify the effect of tirzepatide on blood pressure and lipid profiles across randomized controlled trials.
Does tirzepatide improve blood pressure and lipid profiles?
Meta-Analysis
Does tirzepatide improve blood pressure and lipid profiles?
Tirzepatide provides dose-dependent, clinically meaningful improvements in blood pressure and lipid profiles, suggesting potential cardiovascular benefits beyond glycemic control.
Answers are grounded in this paper and cite their sources.
Tirzepatide reduces BP and improves lipids independent of dose; reinforces cardiometabolic benefits beyond glycemic control in T2D.
AIM: To perform a meta-analysis to quantify the effect of tirzepatide on blood pressure and lipids. METHODS: PubMed, Ovid/Medline, Web of Science, Scopus, Cochrane Library and CINAHL databases were screened and the randomized controlled trials evaluating the effects of tirzepatide on either blood pressure or lipid profiles were included. RESULTS: Seven randomized controlled trials have investigated the effects of tirzepatide on blood pressure and lipid profiles. Regardless of the dose administered, tirzepatide resulted in significant decreases in systolic blood pressure of median -4.20 (95% confidence interval [CI] -5.17 to -3.23) mmHg for 5 mg, -5.34 (-6.31 to -4.37) mmHg for 10 mg, and -5.77 (-6.73 to -4.81) mmHg for 15 mg. At all three once-weekly doses, tirzepatide treatment resulted in significant decreases in total cholesterol levels: median -3.76% (95% CI -5.20% to -2.31%) for 5 mg; -4.63% (-6.07% to -3.19%) for 10 mg; and -5.93% (-7.36% to -4.49%) for 15 mg. Additionally, tirzepatide treatment led to increased high-density lipoprotein (HDL) cholesterol levels and decreased low-density lipoprotein (LDL) cholesterol and triglyceride levels. CONCLUSIONS: Tirzepatide induced clinically meaningful reductions in the levels of systolic and diastolic blood pressure, total cholesterol, LDL cholesterol and triglycerides, along with increases in the level of HDL cholesterol.
No takes yet. Share an insight, caveat, or question.
Kanbay et al. (2023) reported a meta-analysis. Tirzepatide was evaluated on Systolic blood pressure reduction (5 mg dose) (Median difference -4.20 mmHg, 95% CI -5.17 to -3.23). Tirzepatide significantly reduced systolic blood pressure (median -4.20 mmHg, 95% CI -5.17 to -3.23 for 5 mg) and improved lipid profiles across 5 mg, 10 mg, and 15 mg once-weekly doses.
Synapse has enriched 10 related papers. Consider them for comparative context: